S. Louise Phanstiel is Director at MYRIAD GENETICS INC (MYGN). They have made 10 open-market trades across 3 companies since 2013, most recently 2026-08-14.
CIK 0001471518
7 open-market purchases totalling $3.4M since 2013, against 3 sales. Across 6 scored buys the stock is up 11.9% at ninety days, and 8.5 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| BFLY | 300,461 | $2.2M |
| MYGN | 341,652 | $1.4M |
| VSTM | 26,500 | $230K |
| Total | $3.8M |
Shares reported on the most recent Form 4, priced at the 2026-08-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 29% | 29% | 33% |
| Avg Move | -8.7% | -0.9% | +11.9% |
| Alpha | -6.7% | -0.4% | +8.5% |
| Scored | 7 | 7 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BFLY | BUY | 2026-08-14 | 2026-08-17 | $8.68 | $1000K | -3.8% | -19.9% | — |
| MYGN | BUY | 2026-02-25 | 2026-02-27 | $4.73 | $495K | +0.0% | -13.8% | -16.8% |
| BFLY | BUY | 2025-12-15 | 2025-12-17 | $3.08 | $1.1M | +16.5% | +26.8% | +30.2% |
| BFLY | SELL | 2024-09-13 | 2024-09-13 | $1.96 | $235K | -18.9% | -8.9% | +86.3% |
| MYGN | SELL | 2021-08-05 | 2021-08-06 | $35.04 | $3.4M | -4.0% | +3.1% | -11.1% |
| MYGN | BUY | 2020-11-11 | 2020-11-12 | $16.62 | $499K | +10.0% | +8.9% | +66.4% |
| MYGN | SELL | 2015-12-08 | 2015-12-09 | $44.00 | $220K | -0.5% | -0.3% | -11.8% |
| VSTM | BUY | 2014-12-29 | 2014-12-31 | $8.54 | $85K | -27.9% | -2.7% | -2.7% |
| VSTM | BUY | 2013-06-12 | 2013-06-13 | $9.60 | $43K | -27.9% | -2.7% | -2.7% |
| VSTM | BUY | 2013-06-10 | 2013-06-12 | $9.30 | $112K | -27.9% | -2.7% | -2.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.